Phase Ib Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies
Summary
The purpose of this phase Ib study is to assess the efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors, including pancreatic cancer.
Biomarker testing to determine if patient is eligible will be done during prescreening for the trial.
General Information
NCT#: NCT03102320
Study ID: 15834
Trial Phase: Phase I
Trial Sponsor: Bayer
Therapies Used in This Trial: Gemcitabine, Anetumab Ravtansine